Online citations, reference lists, and bibliographies.
← Back to Search

Pharmacological Enhancing Agents Targeting Cognition In Patients With Alcohol-induced Neurocognitive Disorders: A Systematic Review

Nicolaj Mistarz, K. Andersen, A. Nielsen, A. Goudriaan, T. Michel, Lotte Skøt, Dorthe Grüner Nielsen, A. Mellentin
Published 2021 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Debilitating neurocognitive deficits are seen in alcohol use disorders (AUD) and Wernicke-Korsakoff's syndrome (WKS). These shared characteristics suggest a spectrum of alcohol-induced neurocognitive disorders (AIND). Cognitive pharmacological enhancing agents (CPEA) have been examined in the treatment of other psychiatric disorders, but little is known about the effects of these agents on AINDs. Our aim was to synthesize the evidence for the effectiveness of CPEAs on AINDs. Databases were searched for controlled trials examining CPEAs on AUD, WKS, and alcohol-related dementia (ARD). Eligible studies were included in a qualitative synthesis and a quality assessment was conducted. The search identified 23 studies (4 ≤ ns ≤ 98). Evidence suggests that modafinil may improve executive functions in AUD and ARD, but this effect may only be present in patients with severe deficits. The studies were rated as having a moderate risk of bias. Despite the promising effects of modafinil, small samples and inconsistent evidence deem the results preliminary. More research is warranted examining the effects of transdiagnostic CPEAs on deficits across AINDs.
This paper references
10.1080/00223980.1945.9917223
A Standardized Memory Scale for Clinical Use
D. Wechsler (1945)
10.1037/H0049234
Short-term retention of individual verbal items.
L. R. Peterson (1959)
10.1001/ARCHPSYC.1961.01710120031004
An inventory for measuring depression.
A. Beck (1961)
10.7326/0003-4819-75-5-824_2
The Wernicke-Korsakoff syndrome. A clinical and pathological study of 245 patients, 82 with post-mortem examinations.
M. Victor (1971)
10.1001/jama.1972.03190290075032
The Wernicke-Korsakoff Syndrome: A Clinical and Pathological Study of 245 Patients, 82 With Post-Mortem Examinations
D. W. Goodwin (1972)
10.1016/0022-3956(75)90026-6
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
M. Folstein (1975)
10.1002/ANA.410070513
Memory enhancement in Korsakoff's psychosis by clonidine: Further evidence for a noradrenergic deficit
W. Mcentee (1980)
10.1016/0166-4328(83)90011-6
Korsakoff's psychosis: Noradrenergic systems and cognitive impairment
R. Mair (1983)
10.1530/ACTA.0.1040177
Lack of effect of desglycinamide-arginine-vasopressin (DGAVP) on memory in patients with korsakoff's syndrome.
F. Laczi (1983)
10.1097/00002826-198602000-00007
Noradrenergic and cholinergic agents in Korsakoff's syndrome
O'Donnell Vm (1986)
10.1300/J251V07N03_08
Treatment of alcoholic organic brain syndrome with the serotonin reuptake inhibitor fluvoxamine: a preliminary study.
J. Stapleton (1988)
10.1001/ARCHPSYC.1989.01810070043008
Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Preliminary findings.
P. Martin (1989)
10.1016/0278-5846(90)90101-L
On the treatment of the alcoholic organic brain syndrome with an alpha-adrenergic agonist modafinil: double-blind, placebo-controlled clinical, psychometric and neurophysiological studies
B. Saletu (1990)
10.1037/H0054651
Studies of interference in serial verbal reactions.
J. Stroop (1992)
World Health Organization (1992)
10.1159/000118950
Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil.
B. Saletu (1993)
10.1017/S0033291700028440
Korsakoff's syndrome, cognition and clonidine.
R. O'Carroll (1993)
10.1016/0924-977X(94)00129-Y
Fluvoxamine treatment of alcoholic amnestic disorder
Peter R. Martin (1995)
Structured clinical interview for DSM-IV axis I disorders : SCID-I: clinical version : administration booklet
M. First (1996)
First (1996)
10.1136/pgmj.73.855.27
Wernicke-Korsakoff syndrome.
C. Zubaran (1997)
10.1037//0021-843X.108.1.120
Context-processing deficits in schizophrenia: converging evidence from three theoretically motivated cognitive tasks.
J. Cohen (1999)
10.4088/PCC.V02N0502
Methylphenidate Abuse and Psychiatric Side Effects.
Morton Wa (2000)
10.1002/GPS.338
Anticholinesterase drugs for alcoholic Korsakoff syndrome
I. Angunawela (2001)
10.1093/ALCALC/36.6.553
A case of Korsakoff's syndrome improved by high doses of donepezil.
J. Iga (2001)
10.1016/S0149-7634(02)00067-2
A theory of cognitive control, aging cognition, and neuromodulation
T. Braver (2002)
Alcoholism and the Brain: An Overview
M. Oscar-Berman (2003)
A placebo-controlled study of memantine (Ebixa) in dementia of Wernicke-Korsakoff syndrome.
A. Rustembegović (2003)
Rivastigmine in the treatment of alcohol-induced persisting dementia.
R. Gibson (2003)
10.1038/sj.npp.1300118
Influence of Reboxetine on Salivary MHPG Concentration and Cognitive Symptoms Among Patients with Alcohol-Related Korsakoff's Syndrome
T. Reuster (2003)
10.1007/BF00180841
Cognitive enhancement in Korsakoff's psychosis by clonidine: A comparison with l-Dopa and Ephedrine
R. Mair (2004)
10.1176/APPI.AJP.161.11.1957
Hippocampal volume and depression: a meta-analysis of MRI studies.
P. Videbech (2004)
10.1592/phco.24.4.419.33178
Donepezil for Alcohol‐Related Dementia: A Case Report
Kye Y. Kim (2004)
10.1007/BF00432025
Catecholamine metabolism during clonidine withdrawal
Peter R. Martin (2004)
10.1007/BF02244875
Effects of fluvoxamine treatment on cognitive functioning in the alcoholic Korsakoff syndrome
R. O'Carroll (2005)
10.1007/S11920-005-0032-5
Recent advances in the psychotherapy of addictive disorders
K. Carroll (2005)
10.1093/ALCALC/AGH127
Acetylcholinesterase inhibitors for the treatment of Wernicke-Korsakoff syndrome--three further cases show response to donepezil.
M. Cochrane (2005)
10.1007/s00221-006-0822-y
Time and decision making: differential contribution of the posterior insular cortex and the striatum during a delay discounting task
M. Wittmann (2006)
10.1016/j.pbb.2006.03.004
Thiamine deficiency decreases glutamate uptake in the prefrontal cortex and impairs spatial memory performance in a water maze test
Fabiana M. Carvalho (2006)
10.2146/AJHP060647
Understanding the health impact of alcohol dependence.
T. Cargiulo (2007)
10.1038/nn1846
Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory
S. Vijayraghavan (2007)
10.1001/ARCHNEUR.64.11.1575
Dopamine in drug abuse and addiction: results of imaging studies and treatment implications.
N. Volkow (2007)
10.1007/s11065-007-9038-6
Alcohol: Effects on Neurobehavioral Functions and the Brain
M. Oscar-Berman (2007)
10.1001/ARCHPSYC.64.7.830
Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
D. Hasin (2007)
10.1111/J.1530-0277.2007.00481.X
Cognitive performance in long-term abstinent elderly alcoholics.
G. Fein (2007)
10.1016/B978-044306707-5.50041-9
Chapter 38 – Neuropsychiatric Complications of Substance Abuse
G. Ricaurte (2008)
10.2174/156720208786413415
Consequences of alcohol consumption on neurotransmitters -an overview.
Sukhes Mukherjee (2008)
10.1093/ALCALC/AGM158
Rivastigmine in Wernicke-Korsakoff's syndrome: five patients with rivastigmine showed no more improvement than five patients without rivastigmine.
Han J Luykx (2008)
10.1038/sj.npp.1301534
Modafinil: A Review of Neurochemical Actions and Effects on Cognition
M. Minzenberg (2008)
10.1017/S1461145708008663
The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia.
Y. Cheon (2008)
10.2174/157015908787386069
Dopaminergic and Noradrenergic Contributions to Functionality in ADHD: The Role of Methylphenidate
V. Engert (2008)
10.1007/s00213-008-1127-6
The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks
D. Eagle (2008)
10.1038/sj.npp.1301571
Interaction between BDNF and Serotonin: Role in Mood Disorders
K. Martinowich (2008)
(2008)
10.1016/j.euroneuro.2008.08.006
The dopamine agonist apomorphine differentially affects cognitive performance in alcohol dependent patients and healthy controls
A. Schellekens (2009)
10.1080/00048670802607238
Dopamine vs Noradrenaline: Inverted-U Effects and ADHD Theories
F. Lévy (2009)
10.1111/j.1530-0277.2008.00859.x
Changes in the episodic memory and executive functions of abstinent and relapsed alcoholics over a 6-month period.
A. Pitel (2009)
10.1016/j.jad.2008.06.009
Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives.
E. Bora (2009)
10.1371/journal.pmed.1000097
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
D. Moher (2009)
10.2147/NDT.S5700
Brain-derived neurotrophic factor: role in depression and suicide
Yogesh K. Dwivedi (2009)
10.1371/journal.pmed.1000058
The Preventable Causes of Death in the United States: Comparative Risk Assessment of Dietary, Lifestyle, and Metabolic Risk Factors
G. Danaei (2009)
The neurobehavioral correlates of alcoholism.
Sean B. Rourke (2009)
18. The neurobehavioral correlates of alcoholism
Rourke (2009)
10.1016/j.jaac.2010.08.017
Neurobiology of the adolescent brain and behavior: implications for substance use disorders.
B. Casey (2010)
10.1176/appi.ajp.2010.09091379
Research domain criteria (RDoC): toward a new classification framework for research on mental disorders.
T. Insel (2010)
10.2174/187152710790966597
Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders.
S. Chatterjee (2010)
The Risks Associated With Alcohol Use and Alcoholism
J. Rehm (2011)
10.1016/j.biopsych.2011.03.028
Inverted-U–Shaped Dopamine Actions on Human Working Memory and Cognitive Control
R. Cools (2011)
10.1016/B978-0-12-385506-0.00010-7
Role of the serotonergic system in alcohol dependence: from animal models to clinics.
Y. Sari (2011)
10.1016/j.pbb.2011.03.022
Drug targets for cognitive enhancement in neuropsychiatric disorders
T. Wallace (2011)
10.1016/j.biopsych.2010.04.030
Stereological Approaches to Identifying Neuropathology in Psychosis
K. Dorph-Petersen (2011)
10.1111/j.1530-0277.2011.01540.x
Alcohol and the human brain: a systematic review of different neuroimaging methods.
M. Bühler (2011)
National Institute for Health and Care Excellence (2011)
10.1007/s11065-012-9198-x
Function and Dysfunction of Prefrontal Brain Circuitry in Alcoholic Korsakoff’s Syndrome
M. Oscar-Berman (2012)
10.1177/070674371205700604
The Effectiveness of Psychosocial Modalities in the Treatment of Alcohol Problems in Adults: A Review of the Evidence
G. Martin (2012)
10.2174/157488912800673173
Cholinergic receptor system as a target for treating alcohol abuse and dependence.
S. Rahman (2012)
10.1177/1073858410395147
Hippocampal Volume Reduction in First-Episode and Chronic Schizophrenia
Fulvia Adriano (2012)
10.1016/S0140-6736(13)61611-6
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010
H. Whiteford (2013)
10.1186/alzrt157
Alcohol-related dementia: an update of the evidence
N. Ridley (2013)
10.3389/fpsyt.2013.00045
BDNF and Schizophrenia: From Neurodevelopment to Neuronal Plasticity, Learning, and Memory
R. Nieto (2013)
10.1016/j.biopsych.2012.06.032
Effects of Modafinil on Neural Correlates of Response Inhibition in Alcohol-Dependent Patients
L. Schmaal (2013)
10.3389/fpsyt.2013.00001
Proof of Concept Trial of Dronabinol in Obstructive Sleep Apnea
B. Prasad (2013)
10.1016/S0140-6736(12)61728-0
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
R. Lozano (2013)
10.3233/JPD-130186
Levodopa in the treatment of Parkinson's disease: current status and new developments.
D. Salat (2013)
10.1016/j.biopsych.2012.12.025
Modafinil Modulates Resting-State Functional Network Connectivity and Cognitive Control in Alcohol-Dependent Patients
L. Schmaal (2013)
10.1111/j.1369-1600.2011.00418.x
Widespread and sustained cognitive deficits in alcoholism: a meta‐analysis
K. Stavro (2013)
10.1007/s11065-013-9228-3
A Role for Cognitive Rehabilitation in Increasing the Effectiveness of Treatment for Alcohol Use Disorders
M. Bates (2013)
10.1177/0269881113503505
Effect of modafinil on cognitive functions in alcohol dependent patients: A randomized, placebo-controlled trial
L. Joos (2013)
10.1093/alcalc/agt131
Neuropsychological rehabilitation in alcohol-related brain damage: a systematic review.
Jenny Svanberg (2013)
10.1016/j.euroneuro.2012.10.004
Effect of modafinil on impulsivity and relapse in alcohol dependent patients: A randomized, placebo-controlled trial
L. Joos (2013)
American Psychiatric Association (2013)
10.4103/0971-6866.132750
Neurotransmitters in alcoholism: A review of neurobiological and genetic studies
Niladri Banerjee (2014)
10.1016/j.neuroimage.2013.08.036
Gray matter and intrinsic network changes in the posterior cingulate cortex after selective serotonin reuptake inhibitor intake
C. Kraus (2014)
10.1002/wps.20087
The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology
B. Cuthbert (2014)
10.1017/S0033291714000312
Neural substrates of impulsive decision making modulated by modafinil in alcohol-dependent patients
L. Schmaal (2014)
10.3109/00952990.2014.925467
Citicoline in addictive disorders: a review of the literature
N. Wignall (2014)
10.1038/aps.2013.181
Neuronal nicotinic acetylcholine receptors are important targets for alcohol reward and dependence
Jie Wu (2014)
10.2147/SAR.S45666
Nalmefene: a new approach to the treatment of alcohol dependence
F. Paille (2014)
10.1177/1060028014542270
Improvement of a Woman’s Alcohol-Related Dementia via Off-label Memantine Treatment
U. Bonnet (2014)
10.3109/09687637.2014.924481
Interventions for alcohol-related brain damage (ARBD): Do specific approaches restrict the evolution of comprehensive patient care?
L. Horton (2014)
10.1007/s00213-014-3518-1
Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals
Joseph P. Schacht (2014)
10.1016/j.psychres.2014.05.013
Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression – A systematic review
B. Baune (2014)
10.1037/e637862013-001
Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
G. Arbanas (2015)
10.1016/j.brainres.2015.03.025
Corticostriatal BDNF and alcohol addiction
M. Logrip (2015)
10.3389/fnins.2015.00144
Targeting glutamate uptake to treat alcohol use disorders
P. Rao (2015)
10.1111/acer.12669
Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment.
R. Litten (2015)
10.1016/j.euroneuro.2015.04.014
Cognitive enhancing agents in schizophrenia and bipolar disorder
A. Vreeker (2015)
10.1097/HRP.0000000000000079
Pharmacotherapy for Alcohol Use Disorder: Current and Emerging Therapies
R. Swift (2015)
10.1186/s12991-014-0039-6
Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study
N. Hashimoto (2015)
10.1038/tp.2015.41
D-cycloserine to enhance extinction of cue-elicited craving for alcohol: a translational approach
J. MacKillop (2015)
10.1093/ijnp/pyv082
The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
J. Rosenblat (2015)
10.2147/NDT.S76700
Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses
B. Bortolato (2015)
10.1186/s12991-015-0065-z
The relationship between brain-derived neurotrophic factor and cognitive functions in alcohol-dependent patients: a preliminary study
Changwoo Han (2015)
10.1016/j.alcohol.2015.09.001
Alcohol-induced alterations in dopamine modulation of prefrontal activity.
H. Trantham-Davidson (2015)
10.3389/fnins.2015.00011
Visual-induced expectations modulate auditory cortical responses
Virginie van Wassenhove (2015)
10.1111/acer.12661
Moving the Alcohol Addiction RDoC forward.
K. Sher (2015)
10.2217/NMT-2016-0030
Alcohol-related cognitive impairment: current trends and future perspectives.
Victoria Hayes (2016)
10.1016/j.neuropharm.2015.10.034
BDNF – a key transducer of antidepressant effects
C. Björkholm (2016)
10.1515/tnsci-2016-0007
The serotonergic system and cognitive function
D. Svob Strac (2016)
10.1093/ijnp/pyv135
Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression
M. Udina (2016)
10.1080/15504263.2016.1146383
Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders
M. Sofuoglu (2016)
10.1016/j.euroneuro.2016.08.011
Cognitive enhancement treatments for bipolar disorder: A systematic review and methodological recommendations
K. Miskowiak (2016)
10.1186/s12916-015-0545-7
Cancer and fertility preservation: international recommendations from an expert meeting
M. Lambertini (2016)
10.1016/j.biopsych.2015.12.020
A Critical Role of Brain-Derived Neurotrophic Factor in Alcohol Consumption
S. Pandey (2016)
10.1186/s12916-016-0560-3
Cognitive remission: a novel objective for the treatment of major depression?
B. Bortolato (2016)
10.1017/S0033291717000721
Problematic alcohol use and reduced hippocampal volume: a meta-analytic review
S. Wilson (2017)
10.1007/s10654-017-0225-3
Alcohol consumption and dementia risk: a dose–response meta-analysis of prospective studies
W. Xu (2017)
10.2147/NDT.S130078
Korsakoff’s syndrome: a critical review
N. Arts (2017)
10.1016/j.biopsych.2016.12.029
Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study
D. Quelch (2017)
10.1007/s10654-017-0252-0
The combined association of alcohol consumption with dementia risk is likely biased due to lacking account of death cases
N. Binder (2017)
10.1111/acer.13431
Executive Functions, Memory, and Social Cognitive Deficits and Recovery in Chronic Alcoholism: A Critical Review to Inform Future Research
A. Le Berre (2017)
10.1055/s-0043-114670
Erythropoietin for Cognitive Deficits Associated with Schizophrenia, Bipolar Disorder, and Major Depression: A Systematic Review.
Xian-Bin Li (2018)
10.3389/fpsyt.2018.00001
Correlations among Psychological Resilience, Self-Efficacy, and Negative Emotion in Acute Myocardial Infarction Patients after Percutaneous Coronary Intervention
N. Liu (2018)
10.3389/fpsyt.2018.00091
Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease
W. Hsu (2018)
10.1111/add.14234
Global statistics on alcohol, tobacco and illicit drug use: 2017 status report
A. Peacock (2018)
10.1017/S1092852918001426
Cognitive impairment in substance use disorders
Tatiana Ramey (2018)
10.1016/j.psym.2018.03.011
Beyond Thiamine: Treatment for Cognitive Impairment in Korsakoff's Syndrome.
Justin M Johnson (2018)
10.1016/S2215-0366(18)30337-7
The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Louisa Fiona Alize Damian Holly Ana Harvey Janni Mohsen M Degenhardt Charlson Ferrari Santomauro Erskine Man (2018)
10.1111/adb.12668
Alcohol‐induced cognitive deficits are associated with decreased circulating levels of the neurotrophin BDNF in humans and rats
Daniel Silva-Peña (2018)
10.1007/s11065-018-9369-5
A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples
Catherine E. Prado (2018)
10.1037/pha0000161
Effects of Varenicline on Cognitive Performance in Heavy Drinkers: Dose-Response Effects and Associations With Drinking Outcomes
Walter Roberts (2018)
10.1097/YCO.0000000000000378
Cognitive dysfunction in major depressive disorder
M. J. Knight (2018)
10.1177/0269881118780010
Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?
E. Beraha (2018)
Beraha (2018)
10.3389/fpsyt.2019.00676
White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?
E. Schepers (2019)
10.1136/bmj.l5274
Immediate impact of minimum unit pricing on alcohol purchases in Scotland: controlled interrupted time series analysis for 2015-18
A. O’Donnell (2019)
10.1007/s00213-019-05345-6
Effects of the monoamine stabilizer (-)OSU6162 on cognitive function in alcohol dependence
L. Khemiri (2019)
10.1093/arclin/acy106
Widespread Cognitive Deficits in Alcoholism Persistent Following Prolonged Abstinence: An Updated Meta-analysis of Studies That Used Standardised Neuropsychological Assessment Tools.
S. Crowe (2019)
10.1177/0269881118822157
Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials
Chun-Hung Chang (2019)
10.3389/fphar.2019.01087
Mild Effect of Nalmefene on Alcoholic Cue-Induced Response Invigoration in Alcohol Use Disorder Without Accompanying Changes in Electrophysiological Signatures of Early Visual Processing and Executive Control
B. Gál (2019)
10.1136/bmj.l4898
RoB 2: a revised tool for assessing risk of bias in randomised trials
J. Sterne (2019)
10.1016/j.euroneuro.2019.10.014
The effects of nalmefene on emotion processing in alcohol use disorder – A randomized, controlled fMRI study
S. Vollstädt-Klein (2019)
10.1016/S2215-0366(19)30222-6
Psychiatric comorbidities in alcohol use disorder.
Alvaro Castillo-Carniglia (2019)
10.1016/j.schres.2019.05.019
Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials
W. Zheng (2019)
10.1111/acer.13928
A Randomized, Double‐Blind, Placebo‐Controlled Trial of Citicoline in Patients with Alcohol Use Disorder
E. Brown (2019)
10.1017/S1092852918001050
Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder
M. Solmi (2019)
10.3389/fpsyt.2019.00098
Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review
K. Butler (2019)
10.3389/fphar.2019.00001
Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs
Marianna A Zolotovskaia (2019)
10.1017/S0033291719003660
Brain structural effects of treatments for depression and biomarkers of response: a systematic review of neuroimaging studies
V. Enneking (2019)
10.1017/S0033291719002253
Cognitive paths from trauma to posttraumatic stress disorder: a prospective study of Ehlers and Clark's model in survivors of assaults or road traffic collisions
Esther T. Beierl (2019)
10.1007/s00213-019-05192-5
Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals
W. Logge (2019)
22. Vasopressors and inotropes
Zimmerman (2019)
Veritas Health Innovation (2019)
10.1017/S109285292000173X
Effect of Vortioxetine in Subjects with Major Depressive and Alcohol Use Disorders: A Six-Months Retrospective Analysis.
M. Di Nicola (2020)
10.1017/S0033291720002925
A systematic review of treatments for alcohol-related cognitive impairment: lessons from the past and gaps for future interventions
E. Caballeria (2020)
10.1186/s13643-019-1220-4
Long-term effects of alcohol consumption on cognitive function: a systematic review and dose-response analysis of evidence published between 2007 and 2018
Sue E Brennan (2020)
10.1016/j.neuropharm.2020.108352
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease
G. Marucci (2021)



Semantic Scholar Logo Some data provided by SemanticScholar